Orthopedic Surgery Doctors in Albemarle, NC Accepting Medicare

6 Orthopedic Surgery doctors found. Showing 1 - 6

Jack Frank Rocco, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 Yadkin St, Ste 101, Albemarle, NC 28001 Phone: 980-323-5425

William C. Ramsey, Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 105 Yadkin St, Ste 101, Albemarle, NC 28001 Phone: 704-983-5195    Fax: 704-512-4838

Scott Anderson Sherrill, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 Yadkin St, Ste 101, Albemarle, NC 28001 Phone: 980-323-5425

Mr. Surendrapal Sihgh Mac, MD Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 816 N 3rd Street, Albemarle, NC 28001 Phone: 704-983-3314    Fax: 704-983-3315

Timothy Chester Gajewski, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 Yadkin St, Ste 101, Albemarle, NC 28001 Phone: 980-323-5425

Joseph Zucker, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 105 Yadkin St, Ste 101, Albemarle, NC 28001 Phone: 980-323-5425

News Archive

Is American obesity rate on the decline? Survey reports encouraging

Latest findings showed that for the first time "normal" beat out "overweight." The survey however found that 61.6% of Americans were in the categories of either "overweight" or "obese". The survey found 35.8 percent of Americans to be overweight, compared with 36.0 percent a year ago, and 25.8 percent obese, down from 26.6 percent last year.

Study evaluates safety, efficacy and tolerability of probiotics for irritable bowel syndrome

A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis, Bifidobacterium infantis 35624, the sole ingredient in Align (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study.

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

Read more Medical News

› Verified 7 days ago